Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2-metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.

被引：0

作者：

Bardia, Aditya

Rugo, Hope S.

Cortes, Javier

Tolaney, Sara M.

Schmid, Peter

Motwani, Monica

Yoon, Oh Kyu

Boice, Jillian

Zhuo, Luting

Marme, Frederik

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Med Oncol, Canc Ctr, Boston, MA USA

[2] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Int Breast Canc Ctr IBCC, Med Oncol Dept, Pangaea Oncol, Madrid, Spain

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[5] Queen Mary Univ London, Barts Canc Inst, London, England

[6] Gilead Sci Inc, Foster City, CA USA

[7] Heidelberg Univ, Med Fac Mannheim, Dept Obstet & Gynecol, Mannheim, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1082

引用

页数：1